Research advances on ADAM28 expression and ADAM28-mediated tumor metastasis.
10.7534/j.issn.1009-2137.2014.04.049
- Author:
Xiao-Lu ZHU
1
;
Qian-Ming WANG
1
;
Fei-Er FENG
1
;
Xing-Long ZHENG
2
;
Xiao-Hui ZHANG
3
Author Information
1. Institute of Hematology and People's Hospital, Peking University, Beijing 100044, China.
2. Institute of Hematology and People's Hospital, Peking University, Beijing 100044, China
3. Institute of Hematology and People's Hospital, Peking University, Beijing 100044, China. E-mail: zhangxh100@sina.com.
- Publication Type:Journal Article
- MeSH:
ADAM Proteins;
metabolism;
Cell Adhesion;
Connective Tissue Growth Factor;
metabolism;
Humans;
Insulin-Like Growth Factor Binding Protein 3;
metabolism;
Neoplasm Metastasis;
Neoplasms;
pathology;
von Willebrand Factor;
metabolism
- From:
Journal of Experimental Hematology
2014;22(4):1142-1147
- CountryChina
- Language:Chinese
-
Abstract:
A disintegrin-metalloproteinase 28 (ADAM28) is one of important members of ADAM family, that is involved in various biological events including cell adhesion, proteolysis, growth and metastasis of solid tumors and hematological malignancies. Studies have shown that ADAM28 is highly expressed in several human tumors, such as lung, breast and bladder cancers, and chronic lymphocytic leukemia, and its tissue expression levels correlate with cancer metastasis. ADAM28-mediated cancer cell metastasis may be related with the cleavage of von Willebrand's factor (vWF), insulin-like growth factor binding protein-3 (IGFBP-3) and connective tissue growth factor (CTGF), as well as the promoting PSGL-1/P-selectin-mediated cell adhesion. This review summarizes the basic and translational aspects of ADAM28 biology that might stimulate the interest in ADAM28 research and discovery of novel ADAM28 targets, providing potential novel therapies for metastatic cancers.
